IS Pharma plc (AIM: ISPH), results marginally miss estimates but no big deal in the grand scheme
The company, which provides specialist pharmaceuticals and equipment in core areas such as Oncology and Neurology saw revenue up 17% to £14.2m (2009: £12.2m).
This includes £0.7m from the Volplex and Isoplex Distribution and Sale agreement. Product sales were up 19% to £13.4m (2009: £11.2m) and pre-tax profit up 30% to £2.6m (2009: £2.0m) post exceptional items of £0.4m (2009: £0.6m). Basic earnings per share were 7.3p (2009: 9.1p). Consensus estimates were for pre-tax profit of £2.98m and eps of 8.23p, however, there was a big spread between the 2 analysts covering this one (6.7p to 9.6p!). Cash generated from operations was up 24% to £3.1m (2009: £2.5) and cash balances at the year end were £4.2m (2009: £6.0m). During the year the Group…